Cargando…

Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies

BACKGROUND: Surrogate endpoints (i.e., intermediate endpoints intended to predict for patient-centered outcomes) are increasingly common. However, little is known about how surrogate evidence is handled in the context of health technology assessment (HTA). OBJECTIVES: 1) To map methodologies for the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciani, Oriana, Grigore, Bogdan, Blommestein, Hedwig, de Groot, Saskia, Möllenkamp, Meilin, Rabbe, Stefan, Daubner-Bendes, Rita, Taylor, Rod S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108112/ https://www.ncbi.nlm.nih.gov/pubmed/33719711 http://dx.doi.org/10.1177/0272989X21994553

Ejemplares similares

Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence
por: Ciani, Oriana, et al.
Publicado: (2022)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Surrogate endpoints in trials: a call for better reporting
por: Ciani, Oriana, et al.
Publicado: (2022)

A call for better reporting of trials using surrogate primary endpoints
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Scoping and targeted reviews to support development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: protocol
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Treatment effect bias in randomised controlled trials using surrogate outcomes: a preliminary cohort study analysis
por: Ciani, Oriana, et al.
Publicado: (2011)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges
por: Daubner-Bendes, Rita, et al.
Publicado: (2021)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
por: Ciani, Oriana, et al.
Publicado: (2023)

A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses
por: Xie, Wanling, et al.
Publicado: (2019)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges
por: Federici, Carlo, et al.
Publicado: (2021)

Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Surrogate endpoints in early prostate cancer research
por: Williams, Scott
Publicado: (2018)

Surrogate endpoints… Uncommon for a common man!
por: Kumar, Ashish
Publicado: (2019)

Surrogate Endpoints for Late Kidney Transplantation Failure
por: Naesens, Maarten, et al.
Publicado: (2022)

Surrogate endpoints in advanced sarcoma trials: a meta-analysis
por: Savina, Marion, et al.
Publicado: (2018)

Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries
por: Kovács, Sandor, et al.
Publicado: (2022)

HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES: A SURVEY OF NON-EUROPEAN UNION AGENCIES
por: Ciani, Oriana, et al.
Publicado: (2015)

Bayesian hierarchical meta‐analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data
por: Papanikos, Tasos, et al.
Publicado: (2020)

Real‐world evidence in health technology assessment of high‐risk medical devices: Fit for purpose?
por: Klein, Philip, et al.
Publicado: (2022)

Statistical evaluation of surrogate endpoints: a systematic review
por: Ensor, Hannah, et al.
Publicado: (2013)

Bivariate network meta‐analysis for surrogate endpoint evaluation
por: Bujkiewicz, Sylwia, et al.
Publicado: (2019)

Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma
por: Medeiros, Felipe A.
Publicado: (2017)

Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study
por: Ciani, Oriana, et al.
Publicado: (2013)

Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria
por: Jeeyapant, Atthanee, et al.
Publicado: (2017)

Surrogate endpoints and competing risk of death in cardiac arrest research
por: McCredie, Victoria A., et al.
Publicado: (2016)

Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints
por: Bujkiewicz, Sylwia, et al.
Publicado: (2015)

The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018
por: Schuster Bruce, Catherine, et al.
Publicado: (2019)

Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021
por: Ciani, Oriana, et al.
Publicado: (2023)

Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study
por: Wallach, Joshua D., et al.
Publicado: (2018)

Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?
por: Lathia, Chetan D.
Publicado: (2002)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
por: Bikdeli, Behnood, et al.
Publicado: (2017)

Binary surrogate endpoints in clinical trials from the perspective of case definitions
por: HAHN, ANDREAS, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n6v6nj8c9vu0bk65ffs53m8jdh